GENTILE, Ivan
 Distribuzione geografica
Continente #
AS - Asia 13.940
NA - Nord America 10.617
EU - Europa 8.699
SA - Sud America 1.541
AF - Africa 393
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 6
Totale 35.216
Nazione #
US - Stati Uniti d'America 10.097
SG - Singapore 6.000
RU - Federazione Russa 4.254
CN - Cina 2.814
VN - Vietnam 2.558
IT - Italia 1.668
BR - Brasile 1.249
HK - Hong Kong 1.016
DE - Germania 546
NL - Olanda 504
FR - Francia 454
JP - Giappone 293
CA - Canada 292
FI - Finlandia 279
GB - Regno Unito 255
IN - India 229
KR - Corea 202
IE - Irlanda 182
BD - Bangladesh 176
MX - Messico 131
AR - Argentina 125
ZA - Sudafrica 111
IQ - Iraq 106
UA - Ucraina 106
CI - Costa d'Avorio 94
PL - Polonia 89
SE - Svezia 71
PH - Filippine 69
TH - Thailandia 65
AT - Austria 58
ES - Italia 56
ID - Indonesia 54
TR - Turchia 47
EC - Ecuador 45
PK - Pakistan 42
TW - Taiwan 42
LT - Lituania 35
MA - Marocco 33
UZ - Uzbekistan 32
EG - Egitto 30
CO - Colombia 29
VE - Venezuela 27
KE - Kenya 24
SA - Arabia Saudita 23
JM - Giamaica 21
AE - Emirati Arabi Uniti 20
CL - Cile 20
JO - Giordania 20
DZ - Algeria 19
TN - Tunisia 17
CZ - Repubblica Ceca 15
PY - Paraguay 15
BE - Belgio 14
CH - Svizzera 14
KZ - Kazakistan 12
NP - Nepal 12
AU - Australia 11
ET - Etiopia 11
IR - Iran 11
AL - Albania 10
CR - Costa Rica 10
LV - Lettonia 10
MY - Malesia 10
OM - Oman 10
RS - Serbia 10
DO - Repubblica Dominicana 9
IL - Israele 9
PE - Perù 9
RO - Romania 9
SV - El Salvador 9
UY - Uruguay 9
AZ - Azerbaigian 8
BO - Bolivia 8
LB - Libano 8
NI - Nicaragua 8
BG - Bulgaria 7
NG - Nigeria 7
SN - Senegal 7
AO - Angola 6
NZ - Nuova Zelanda 6
PS - Palestinian Territory 6
GR - Grecia 5
GT - Guatemala 5
HN - Honduras 5
HR - Croazia 5
PA - Panama 5
PR - Porto Rico 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
AF - Afghanistan, Repubblica islamica di 4
BW - Botswana 4
DK - Danimarca 4
EU - Europa 4
GE - Georgia 4
HU - Ungheria 4
KW - Kuwait 4
LU - Lussemburgo 4
MK - Macedonia 4
MN - Mongolia 4
QA - Qatar 4
Totale 35.113
Città #
Singapore 2.958
San Jose 1.916
Moscow 1.045
Ashburn 1.020
Hong Kong 968
Hefei 913
Ho Chi Minh City 705
Beijing 686
Chandler 620
Hanoi 594
Naples 557
Santa Clara 475
Amsterdam 407
Los Angeles 390
The Dalles 353
Lauterbourg 293
Tokyo 272
Millbury 246
New York 235
Munich 204
Seoul 168
Des Moines 151
Boston 143
Redondo Beach 138
Princeton 136
Dallas 134
São Paulo 134
Nanjing 129
Napoli 129
Buffalo 124
Da Nang 116
Haiphong 105
Frankfurt am Main 101
Ottawa 100
Orem 90
Lawrence 89
Seattle 86
Warsaw 78
Rome 76
Montreal 75
Chicago 73
Nuremberg 72
Turku 72
Boardman 68
Brooklyn 65
Houston 65
Wilmington 63
Helsinki 56
Mexico City 56
Milan 55
Council Bluffs 52
Chennai 50
Denver 50
Johannesburg 50
Baghdad 48
London 46
Poplar 46
Stockholm 46
Atlanta 45
Toronto 43
Nanchang 42
Jacksonville 40
Rio de Janeiro 39
San Francisco 39
Hải Dương 38
Phoenix 37
Biên Hòa 36
Dublin 36
Bangkok 31
Can Tho 30
Shenyang 29
Tashkent 29
Falkenstein 28
Lappeenranta 28
Manchester 28
Hebei 26
Washington 26
Belo Horizonte 24
Ninh Bình 24
Querétaro 24
Thái Nguyên 24
Tianjin 24
Curitiba 23
Düsseldorf 22
Jiaxing 22
Ankara 21
Charlotte 21
Porto Alegre 21
Dhaka 20
Nairobi 20
Brasília 19
Bắc Giang 19
Changsha 19
New Delhi 19
Vienna 19
Bến Tre 18
Guangzhou 18
Guarulhos 18
Pune 18
Tân Tiến 18
Totale 19.317
Nome #
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 190
[HBV and pregnancy]. 184
Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection 180
A transient increase in the serum ancas in patients with sars-cov-2 infection: A signal of subclinical vasculitis or an epiphenomenon with no clinical manifestations? a pilot study 178
Febbre di origine sconosciuta (FUO): nostra casistica 177
Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study 173
Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19 170
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) 169
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 168
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy 168
Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves 166
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 166
Peri-transplant Treatment with Ceftaroline in Kidney Transplant Recipients at Risk of Donor-derived MRSA Infections: A Case Series 160
A CASE OF PEGYLATED INTERFERON ALPHA-RELATED DIABETIC KETOACIDOSIS: CAN THIS COMPLICATION BE AVOIDED? 160
Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. 159
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 158
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C 158
A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19 157
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 155
Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19-An Observational Retrospective Study 154
Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy 153
Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: Results from a prospective study 153
Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals 153
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19) 153
Asunaprevir for hepatitis C: A safety evaluation 152
Hemolytic anemia during pegylated interferon alpha 2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. A case report 151
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study 151
Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 150
Rara e grave manifestazione dell’infezione da HHV-6: la sindrome DRESS. 149
COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study 148
Pre-existing chronic kidney disease (CDK) was not associated with a severe clinical outcome of hospitalized COVID-19: results of a case-control study in Southern Italy 148
Diabetes and COVID-19: The potential role of mTOR 148
A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C 148
Low vitamin D levels are associated with the presence of serum cryoglobulins in patients with chronic HCV infection 148
HIV and hepatitis C virus: facts and controversies 147
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. 147
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 147
A SIMPLE NONINVASIVE SCORE PREDICTS GASTROESOPHAGEAL VARICES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS. 146
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 145
Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection 145
Investigational direct-acting antivirals in hepatitis C treatment: The latest drugs in clinical development 144
Does compulsory vaccination limit personal freedom? Ethical issues 144
Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis 143
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study 142
Lactate dehydrogenase and PaO2/FiO2 ratio at admission helps to predict CT score in patients with COVID-19: An observational study 142
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5) 142
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art 142
Further findings concerning endothelial damage in covid-19 patients 142
The MBL2 genotype relates to COVID-19 severity and may help to select the optimal therapy 141
Vitamin D deficiency is an independent risk factor and is predictor of infections in patients affected by HCV-related liver cirrhosis 141
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naive for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014 141
mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study 140
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 140
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) 140
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study 139
Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis 139
The tnfrsf13c h159y variant is associated with severe covid-19: A retrospective study of 500 patients from southern italy 139
B-Type Natriuretic Peptides and High-Sensitive Troponin I as COVID-19 Survival Factors: Which One Is the Best Performer? 138
Cytometric analysis of patients with COVID-19: what is changed in the second wave? 138
Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients 137
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. 137
A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir 137
A survey on antibiotic therapy knowledge among physicians of a tertiary care and university hospital 137
Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves? 137
Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy 136
Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19 135
Beclabuvir for the treatment of hepatitis C 135
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort) 135
Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients 135
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 134
Trabecular bone score assessed by dual-energy X ray absorption predicts vertebral fractures in HIV infected young adults 134
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study 133
Bulevirtide Treatment of Hepatitis Delta Virus Infection in a Kidney Transplant Recipient: A Case Report 133
Prevalenza di infezioni da CMV, HHV-6 o EBV in bambini con disturbi dello spettro autistico. 132
Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials 132
Serum Galectin-3 and Aldosterone: potential biomarkers of cardiac complications in patients with COVID-19 132
Microbiota and hepatitis C virus in the era of direct-acting antiviral agents 131
COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy) 131
Virological patterns of HCV patients with failure to interferon-free regimens 131
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 131
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 131
Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. 130
Prevalence of HSV1/2 congenital infection assessed through genome detection on dried blood spot in individuals with autism spectrum disorders 130
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 130
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 129
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience 129
Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. 129
Antibiotic prophylaxis and risk of infections in thyroid surgery: Results from a national study (UEC - Italian Endocrine Surgery Units Association) 129
Serum KL-6 could represent a reliable indicator of unfavourable outcome in patients with COVID-19 pneumonia 129
Regulatory noncoding and predicted pathogenic coding variants of ccr5 predispose to severe covid-19 129
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 128
Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge 128
Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study 128
Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience 128
Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center Experience 128
Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage 128
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy 128
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 128
Prevalence of Pneumocystis jirovecii Colonization in Non-Critical Immunocompetent COVID-19 Patients: A Single-Center Prospective Study (JiroCOVID Study) 127
Totale 14.399
Categoria #
all - tutte 108.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.464


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202149 0 0 0 0 0 0 0 0 0 0 21 28
2021/20221.254 19 8 20 11 8 39 24 46 163 78 286 552
2022/20231.962 233 113 53 99 214 209 34 172 316 377 83 59
2023/20241.601 78 222 295 99 94 182 40 153 32 24 233 149
2024/20259.684 367 371 54 170 241 599 980 593 749 1.038 3.573 949
2025/202619.590 2.119 1.669 2.196 2.066 3.263 906 2.290 1.149 2.128 1.229 575 0
Totale 35.807